Compare Oruka Therapeutics Inc. Common Stock (ORKA) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Oruka Therapeutics Inc. Common Stock vs Raytheon Technologies Corp — how do they compare? Oruka Therapeutics Inc. Common Stock trades at $75.2 (market cap $5.18B), while Raytheon Technologies Corp trades at $187.44 (market cap $246.67B). The key difference: Raytheon Technologies Corp is far larger — about 47.6× Oruka Therapeutics Inc. Common Stock's market cap, and Raytheon Technologies Corp pays a 1.6% dividend while Oruka Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Oruka Therapeutics Inc. Common Stock for 0 Days and Raytheon Technologies Corp for 78 Days on average.
| ORKA | RTX | |
|---|---|---|
Market Cap | $5.18B | $246.67B |
Volume | 490,798 | 4,726,714 |
Sector | Health | Industrials |
52-Week High | $113.08 | $225.49 |
52-Week Low | $26.19 | $157.00 |
Typical Hold Time | 0 Days | 78 Days |
Enterprise Value | $4.31B | $277.22B |
Dividend Yield | — | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RTX trades at $186.66, up 0.37% on the day, with a bearish technical signal but strong fundamental momentum. The company reported revenue of $88.60 billion in 2025, with net income of $6.73 billion and a profit margin of 7.59%. Recent earnings beats and a $289 billion backlog highlight robust demand in aerospace and defense. Analyst consensus is bullish with a $233.55 price target, though technical indicators show near-term resistance.
The outlook for RTX is positive, driven by sustained defense spending and commercial aviation recovery. Investment opportunities include earnings growth and dividend yield, while risks involve execution on the large backlog and potential defense budget fluctuations. The stock offers value if it can maintain its growth trajectory amid geopolitical tailwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Oruka Therapeutics Inc. Common Stock
Oruka Therapeutics, Inc. is a clinical-stage biotechnology company developing extended half-life monoclonal antibodies for plaque psoriasis, psoriatic arthritis, and related dermatologic conditions, with lead candidates ORKA-001 and ORKA-002 in clinical trials.
Read more on ORKA →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
